---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-009042"
form_type: "8-K"
ticker: "CVM"
cik: "0000725363"
company_name: "CEL SCI CORP"
filed_at: "2023-07-12T23:59:59+00:00"
generated_at: "2026-06-13T09:39:46.134855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cel-SCI reports Multikine Phase 3 biomarker data: 20% 5-year OS benefit in low PD-L1 head & neck cancer patients

## Summary
- Low PD-L1 subgroup (TPS<10) showed 20% absolute 5-year overall survival advantage for Multikine+SOC vs SOC alone (60% vs 40% alive).
- PD-L1 low subgroup represents >70% of lower-risk patients; hazard ratio 0.68 for LR population all patients.
- Data suggest potential to combine Multikine with checkpoint inhibitors like Keytruda or Opdivo for broader coverage.
- Company filed patent for Multikine use in tumors with low PD-L1 expression.
- Previously reported 14.1% absolute 5-year OS benefit in lower-risk ITT patients; now biomarker confirms effect.

## SEC filing metadata
- accession: 0001654954-23-009042
- form_type: 8-K
- ticker: CVM
- cik: 0000725363
- company_name: CEL SCI CORP
- filed_at: 2023-07-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/725363/000165495423009042/0001654954-23-009042-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/725363/000165495423009042/cvm_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-009042
- JSON: https://secwatch.observer/filing/0001654954-23-009042.json
- Plain text: https://secwatch.observer/filing/0001654954-23-009042.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.